Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: J Hepatol. 2020 May 7;73(4):783–793. doi: 10.1016/j.jhep.2020.04.038

Figure 6.

Figure 6.

NNMT inhibition protects against alcoholic fatty liver development. Ten-week old male C57BL/6N mice were retro-orbitally injected with either Ad-GFP-U6-m-NNMT-shRNA or corresponding control vector, followed by the NIAAA model regimen. (A) Hepatic NNMT protein abundance; (B) Plasma TAG levels, (C) Plasma total cholesterol levels; (D) Plasma glucose levels; (E) The liver TAG levels. (F) H&E staining of liver tissues. Ten-week old male C57BL/6N mice were injected (ip) with either PBS or JBSNF-00008, a chemical inhibitor of NNMT, twice a day in the NIAAA model regimen. (G) The liver TAG levels; (H) H&E staining of liver tissues. AML12 cells were treated with JBSNF-00008 (10 μM), a chemical inhibitor of NNMT, for indicated time durations. (I) Intracellular TAG levels were measured. Data are expressed as mean ± SEM (n = 5–8). Differences between groups were determined using one-way ANOVA analysis (*p < 0.05 versus control vector/PF mice).